Exelixis Inc. has announced that its partner Ipsen has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use $(CHMP)$ regarding CABOMETYX® (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated neuroendocrine tumors. This recommendation is a crucial step towards obtaining final approval from the European Commission, expected in the coming months. The positive CHMP opinion follows the U.S. FDA's approval in March 2025, based on the phase 3 CABINET trial results. This development highlights the ongoing efforts to bring new treatment options to patients in Europe, addressing the need for effective therapies following disease progression.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.